BioSpace News Archive

Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), today announced that the underwriters of its recent public offering of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock have exercised in full their option and purchased an additional 93,750 shares at the public offering price of $20.00 per share.

Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Cowen Healthcare Conference at 8:40 a.m. ET on Tuesday, March 3, 2020, in Boston.

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that it has drawn down the remaining $2.5 million under the $45 million term loan agreement with its current lenders, investment affiliates managed by Solar Capital Partners, LLC.

Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering priced at-the-market under Nasdaq rules, of 7,598,426 shares of its common stock,

Combination of consultancy, training, robotics and newly-acquired patient optimization technologies to benefit patients and healthcare providers

Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, president and chief executive officer, will present at Cowen and Company’s 40th Annual Healthcare Conference in Boston on Monday, March 2, 2020, at 11:20 a.m. (EST).

Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and CF Europe, the federation of 48 national CF Associations in Europe, today announced the completion of enrollment of 502 patients with CF for HIT-CF, a European-based initiative that is paving the path to personalized medicine through the CHOICES clinical trial.

Dovetail Genomics, the industry leader in advanced proximity ligation genomic solutions, today announced the global availability of its latest offerings, Dovetail™ Micro-C and HiChIP Kits.

Feb. 24, 2020 13:00 UTC GERMANTOWN, Md.--( BUSINESS WIRE )-- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for adults with diabetes, presented data that demonstrated real-world use of the Eversense ® CGM System across adult age ranges. Key International Consensus 1 CGM targets were met in many adult patients with